학술논문
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase
Document Type
Letter
Author
Source
In: Haematologica . (Haematologica, April 2024, 109(4):1274-1278)
Subject
Language
English
ISSN
15928721
03906078
03906078